A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer

This study is testing whether adding a chemotherapy drug called Myocet to a standard treatment plan works better at fighting metastatic breast cancer. Researchers want to see if this three-drug combination is safer and more effective for patients whose cancer tests positive for a protein called HER2.

This trial is for adults with HER2-positive breast cancer that has spread to other parts of the body and has not yet been treated with chemotherapy for this stage. You must have a healthy heart and measurable tumors to be eligible.

You will be randomly assigned to receive either the standard two-drug treatment or the new three-drug combination. Throughout the study, doctors will closely monitor your health, tumor size, and heart function to see how your body responds to the medicine.

The study has locations in San Diego, California; Aurora, Colorado; and Coral Springs, Florida. The current status of the study is unknown, so it is best to contact the sites directly to see if they are still enrolling patients.